Article

Global strategies to reduce the price of antiretroviral medicines: Evidence from transactional databases

Boston University School of Medicine, Boston, MA 02118, United States of America.
Bulletin of the World Health Organisation (Impact Factor: 5.11). 08/2009; 87(7):520-8. DOI: 10.2471/BLT.08.058925
Source: PubMed

ABSTRACT To estimate the impact of global strategies, such as pooled procurement arrangements, third-party price negotiation and differential pricing, on reducing the price of antiretrovirals (ARVs), which currently hinders universal access to HIV/AIDS treatment.
We estimated the impact of global strategies to reduce ARV prices using data on 7253 procurement transactions (July 2002-October 2007) from databases hosted by WHO and the Global Fund to Fight AIDS, Tuberculosis and Malaria.
For 19 of 24 ARV dosage forms, we detected no association between price and volume purchased. For the other five ARVs, high-volume purchases were 4-21% less expensive than medium- or low-volume purchases. Nine of 13 generic ARVs were priced 6-36% lower when purchased under the Clinton Foundation HIV/AIDS Initiative (CHAI). Fifteen of 18 branded ARVs were priced 23-498% higher for differentially priced purchases compared with non-CHAI generic purchases. However, two branded, differentially priced ARVs were priced 63% and 73% lower, respectively, than generic non-CHAI equivalents.
Large purchase volumes did not necessarily result in lower ARV prices. Although current plans for pooled procurement will further increase purchase volumes, savings are uncertain and should be balanced against programmatic costs. Third-party negotiation by CHAI resulted in lower generic ARV prices. Generics were less expensive than differentially priced branded ARVs, except where little generic competition exists. Alternative strategies for reducing ARV prices, such as streamlining financial management systems, improving demand forecasting and removing barriers to generics, should be explored.

Download full-text

Full-text

Available from: Matthew P Fox, Aug 14, 2015
0 Followers
 · 
142 Views
  • Source
    • "Finally, the difficulty of measuring results increases along the pathway. Short-run market effects, such as prices and quantity, can commonly be observed with good accuracy in existing central databases (Waning et al. 2009). In contrast, health outcomes, such as cause-specific mortality, are rarely measured accurately in developing countries. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Despite extraordinary global progress in increasing coverage of antiretroviral treatment (ART), the majority of people needing ART currently are not receiving treatment. Both the number of people needing ART and the average ART price per patient-year are expected to increase in coming years, which will dramatically raise funding needs for ART. Several international organizations are using interventions in ART markets to decrease ART price or to improve ART quality, delivery and innovation, with the ultimate goal of improving population health. These organizations need to select those market interventions that are most likely to substantially affect population health outcomes (ex ante assessment) and to evaluate whether implemented interventions have improved health outcomes (ex post assessment). We develop a framework to structure ex ante and ex post assessment of the population health impact of market interventions, which is transmitted through effects in markets and health systems. Ex ante assessment should include evaluation of the safety and efficacy of the ART products whose markets will be affected by the intervention; theoretical consideration of the mechanisms through which the intervention will affect population health; and predictive modelling to estimate the potential population health impact of the intervention. For ex post assessment, analysts need to consider which outcomes to estimate empirically and which to model based on empirical findings and understanding of the economic and biological mechanisms along the causal pathway from market intervention to population health. We discuss methods for ex post assessment and analyse assessment issues (unintended intervention effects, interaction effects between different interventions, and assessment impartiality and cost). We offer seven recommendations for ex ante and ex post assessment of population health impact of market interventions.
    Health Policy and Planning 09/2011; 27(6):467-76. DOI:10.1093/heapol/czr058 · 3.00 Impact Factor
  • Source
    • "iii Third party negotiated price ceiling agreements between manufacturers and governments, similar to those used by the Clinton Foundation HIV/AIDS initiative (CHAI), whereby real cost price þ negotiated returns are negotiated with the antivenom producer, incentives to further cost reduction such as technical improvements or technology transfer are agreed on, and participating governments then enter purchasing agreements. It is noteworthy however that a recent study of these strategies as they are applied to containment of antiretroviral (ARV) drug costs (Waning et al., 2009) found little evidence to support downstream benefits from price pooling of ARVs. Desktop modeling and/or limited trials would need to be conducted to establish clear benefits in the case of antivenoms. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Snakebite envenoming is a neglected public health challenge of compelling importance in many regions of the world, particularly sub-Saharan Africa, Asia, Latin America and Papua-New Guinea. Addressing the problem of snakebite effectively demands an integrated multifocal approach, targeting complex problems and involving many participants. It must comprise: (a) Acquisition of reliable information on the incidence and mortality attributable to snakebite envenoming, and the number of people left with permanent sequelae. (b) Improvements in production of effective and safe antivenoms, through strategies aimed at strengthening the technological capacity of antivenom manufacturing laboratories. (c) Increasing the capacity of low-income countries to produce specific immunogens(snake venoms) locally, and to perform their own quality control of antivenoms. (d) Commitments from regional producers to manufacture antivenoms for countries where antivenom production is not currently feasible. (e) Implementation of financial initiatives guaranteeing the acquisition of adequate volumes of antivenom at affordable prices in low-income countries. (f) Performance of collaborative studies on the safety and effectiveness of antivenoms assessed preclinically and by properly designed clinical trials. (g) Development of antivenom distribution programmes tailored to the real needs and epidemiological situations of rural areas in each country. (h) Permanent training programmes for health staff, particularly in rural areas where snakebites are frequent.(i) Implementation of programmes to support those people whose snakebites resulted in chronic disabilities. (j) Preventive and educational programmes at the community level, with the active involvement of local organizations and employing modern methods of health promotion. Such an integrated approach, currently being fostered by the Global Snake Bite Initiative of the International Society on Toxinology and by the World Health Organization, will help to alleviate the enormous burden of human suffering inflicted by snakebite envenoming.
    Toxicon 11/2009; 56(7):1223-35. DOI:10.1016/j.toxicon.2009.11.020 · 2.58 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This paper describes the design of a DC-DC Converter System which utilizes a high frequency 20 KHz switching circuit to perform power conversion, and which provides a voltage and current regulated DC output. The converter system as described, is capable of delivering up to 5 KW of isolated DC power to a prescribed load. The paper describes pulse width modulated drive methods, power amplifier design, and regulation and control methods as well as discussing thermal design considerations and techniques, and circuit layout considerations used to minimize lead inductances for optimum circuit performance.
    Telephone Energy conference, 1978. INTELEC 78. International; 11/1978
Show more